Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of symptomatic seasonal or perennial allergic rhinitis~* Active rhinoconjunctivitis~* Six week standard treatment before inclusion~* Confirmation of an Immunoglobulin E-mediated response through previous positive skin or in vitro allergen testing~Exclusion Criteria:~* Other immunological immune-mediated diseases such as autoimmune diseases and cancer.~* Unstable chronic disease, such as diabetes, cardiac diseases, chronic kidney failure, chronic hepatic disease.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- DLE plus standard medications (Type: EXPERIMENTAL): DLE + Second generation anti histamines + Nasal corticosteroids DLE 2mg/5 milliliters (mL) P.O. every 24h per 5 days, followed by 2 mg/mL P.O. twice weekly for 5 weeks, follow by 2 mg/5mL per week for 5 weeks.~Second generation anti histamines at standard dosis every 24h, and Nasal corticosteroids two spray released per nostril every 24 h per 11 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).